Kestra Advisory Services’s Catalyst Pharmaceutical CPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.24M Sell
39,421
-480
-1% -$14.2K ﹤0.01% 1678
2026
Q1
$988K Buy
39,901
+742
+2% +$17.7K ﹤0.01% 1742
2025
Q4
$914K Sell
39,159
-20
-0.1% -$446 ﹤0.01% 1725
2025
Q3
$772K Buy
+39,179
New +$806K ﹤0.01% 1766
2021
Q1
Sell
-22,000
Closed -$75K 1888
2020
Q4
$75K Buy
+22,000
New +$73.9K ﹤0.01% 1798

Other funds holding CPRX

Kestra Advisory Services's CPRX Position: Q2 2026 in Review

Kestra Advisory Services reduced its Catalyst Pharmaceutical (CPRX) stake by 1.2% in Q2 2026, selling an estimated $14.2K and leaving 39,421 shares worth $1.24M. The position accounts for ﹤0.01% of the portfolio, ranked #1678.

Kestra Advisory Services first reported a position in CPRX in Q4 2020 and has held it in 5 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Kestra Advisory Services held 39,421 shares of Catalyst Pharmaceutical worth $1.24M as of Q2 2026.
  • Kestra Advisory Services sold 480 Catalyst Pharmaceutical shares in Q2 2026, an estimated $14.2K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Kestra Advisory Services's portfolio in Q2 2026, its #1678 holding.
  • Kestra Advisory Services first reported a position in Catalyst Pharmaceutical in Q4 2020 and has held it in 5 quarters since.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Kestra Advisory Services's 13F filing for Q2 2026, filed 28 Jul 2026.